This Article Abstract Full Text Full Text (PDF) View Related Cardiosource Journal Scan Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jolly, S. S. Articles by Mehta, S. R. Search for Related Content PubMed PubMed Citation Articles by Jolly, S. S. Articles by Mehta, S. R. Related Collections Related Article

Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines

Results From the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) Trial

Sanjit S. Jolly, MD, MSc^_*,_*, David P. Faxon, MD, Keith A.A. Fox, MB, ChB, Rizwan Afzal, MSc^_*, William E. Boden, MD, Petr Widimsky, MD^||, P. Gabriel Steg, MD^¶, Vicent Valentin, MD^#, Andrez Budaj, MD^_**, Christopher B. Granger, MD, Campbell D. Joyner, MD, Susan Chrolavicius, BScN^_*, Salim Yusuf, DPhil^_* and Shamir R. Mehta, MD, MSc^_*

^_* Department of Medicine, Hamilton Health Sciences, Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
Royal Infirmary and University of Edinburgh, Edinburgh, Scotland
Department of Cardiology, University of Buffalo School of Medicine, Buffalo General Hospital, Buffalo, New York
^|| Charles University, Hospital Kralovske Vinohrady, Prague, Czech Republic
^¶ Département de Cardiologie, INSERM U-698, Université Paris 7, AP-HP, Paris, France
^# Hospital Universitari Dr. Peset, Valencia, Spain
^_** Postgraduate Medical School, Department of Cardiology, Grochowski Hospital, Warsaw, Poland
Duke Clinical Research Institute, Duke University, Durham, North Carolina
Department of Medicine, Sunnybrook Health Sciences Center, University of Toronto, Toronto, Ontario, Canada

View larger version (32K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Safety and Efficacy of Fondaparinux Versus Enoxaparin in GP IIb/IIIa and Thienopyridine Subgroups Fondaparinux reduced major bleeding and improved net clinical outcome compared with enoxaparin irrespective of glycoprotein (GP) IIb/IIIa or thienopyridine use. CI = confidence interval; MI = myocardial infarction.

View larger version (30K): [in this window] [in a new window] [Download PPT slide]   Figure 2 Kaplan-Meier Event Curves for Major Bleeding and Net Clinical Outcome for GP IIb/IIIa and Thienopyridine Subgroups Net clinical outcome (death, myocardial infarction, refractory ischemia, or major bleeding). GP = glycoprotein; HR = hazard ratio.

View larger version (33K): [in this window] [in a new window] [Download PPT slide]   Figure 3 In Those Undergoing PCI, the Efficacy and Safety of Fondaparinux Versus Enoxaparin in Those Treated With GP IIb/IIIa Inhibitors or Pre-Treated (6 h) With Thienopyridines or Both In the PCI population, fondaparinux reduced major bleeding compared with enoxaparin regardless of GP IIb/IIIa or thienopyridine pre-treatment. PCI = percutaneous coronary intervention; other abbreviations as in Figure 1.